141 related articles for article (PubMed ID: 27643554)
1. miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1.
Su W; Mo Y; Wu F; Guo K; Li J; Luo Y; Ye H; Guo H; Li D; Yang Z
Biomed Pharmacother; 2016 Dec; 84():123-129. PubMed ID: 27643554
[TBL] [Abstract][Full Text] [Related]
2. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
6. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
7. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5.
Hao GJ; Ding YH; Wen H; Li XF; Zhang W; Su HY; Liu DM; Xie NL
Biochem Biophys Res Commun; 2017 Jul; 488(3):501-508. PubMed ID: 28511796
[TBL] [Abstract][Full Text] [Related]
9. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
12. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
[TBL] [Abstract][Full Text] [Related]
15. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
16. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-25 modulates non-small cell lung cancer cells by targeting CDC42.
Yang T; Chen T; Li Y; Gao L; Zhang S; Wang T; Chen M
Tumour Biol; 2015 Mar; 36(3):1903-11. PubMed ID: 25432132
[TBL] [Abstract][Full Text] [Related]
18. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1.
Ma Z; Cai H; Zhang Y; Chang L; Cui Y
Biochem Biophys Res Commun; 2017 Aug; 490(2):309-316. PubMed ID: 28619508
[TBL] [Abstract][Full Text] [Related]
19. Morin inhibited lung cancer cells viability, growth, and migration by suppressing miR-135b and inducing its target CCNG2.
Yao D; Cui H; Zhou S; Guo L
Tumour Biol; 2017 Oct; 39(10):1010428317712443. PubMed ID: 28975847
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA GAS5 Inhibits Tumorigenesis and Enhances Radiosensitivity by Suppressing miR-135b Expression in Non-Small Cell Lung Cancer.
Xue Y; Ni T; Jiang Y; Li Y
Oncol Res; 2017 Sep; 25(8):1305-1316. PubMed ID: 28117028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]